肠易激综合征与全因及特定病因死亡的时间依赖性关联:英国生物样本库前瞻性队列研究
基于英国生物样本库502,369名参与者、中位随访13.7年的前瞻性队列研究,采用多变量Cox比例风险回归按随访时间段(0-5年、>5-10年、>10年)分析。基线有肠易激综合征者25,697人(5.1%),随访期间共44,499例死亡。肠易激综合征诊断与随访前5年较低的全因死亡(HR=0.70,95%CI=0.62-0.78)和全癌死亡(HR=0.69,95%CI=0.60-0.79)风险强烈相关,该关联随随访时间减弱,但10年后仍呈反向关联(全因:HR=0.89,95%CI=0.84-0.96;全癌:HR=0.87,95%CI=0.78-0.97)。
要点
- 基线肠易激综合征患病率为5.1%(25,697/502,369),中位随访13.7年共44,499例死亡。
- 随访前5年肠易激综合征与全因死亡(HR=0.70,95%CI=0.62-0.78)及全癌死亡(HR=0.69,95%CI=0.60-0.79)风险降低相关。
- 关联随随访时间减弱,10年后全因死亡HR=0.89(95%CI=0.84-0.96)、全癌死亡HR=0.87(95%CI=0.78-0.97)。
核心结论
- 随访早期诊断为肠易激综合征与较低的死亡风险相关,该关联随时间减弱。
- 需要进一步研究生活方式和医疗可及性等特定因素是否解释肠易激综合征与死亡之间的反向关联。
研究设计与样本
- 英国生物样本库前瞻性队列研究,纳入502,369名参与者, mortality数据截至2022年。
- 肠易激综合征定义基于基线自我报告及与初级保健或住院入院数据的链接。
- 采用多变量Cox比例风险回归模型,在分区随访时间段(0-5年、>5-10年、>10年)内估计风险比(HR)和95%置信区间(CI)。
主要发现
- 基线有肠易激综合征病史者25,697人(5.1%),中位随访13.7年共发生44,499例死亡。
- 随访前5年,肠易激综合征诊断与较低的全因死亡风险(HR=0.70,95%CI=0.62-0.78)和全癌死亡风险(HR=0.69,95%CI=0.60-0.79)强烈相关。
- 充分调整后,随访10年后关联仍呈反向(全因死亡:HR=0.89,95%CI=0.84-0.96;全癌死亡:HR=0.87,95%CI=0.78-0.97)。
- 肠易激综合征患者在部分随访时间段内乳腺癌、前列腺癌和结直肠癌死亡风险降低。
局限性
- 需要进一步研究以了解生活方式和医疗可及性等特定因素是否解释肠易激综合征与死亡之间的反向关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, but few studies have evaluated mortality risks among individuals with IBS. We explored the association between IBS and all-cause and cause-specific mortality in the UK Biobank. METHODS: We included 502,369 participants from the UK Biobank with mortality data through 2022. IBS was defined using baseline self-report and linkage to primary care or hospital admission data. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause and cause-specific mortality using multivariable Cox proportional hazards regression models within partitioned follow-up time categories (0-5, >5-10, and >10 years). RESULTS: A total of 25,697 participants (5.1%) had a history of IBS at baseline. After a median follow-up of 13.7 years, a total of 44,499 deaths occurred. Having an IBS diagnosis was strongly associated with lower risks of all-cause (HR = 0.70, 95% CI = 0.62-0.78) and all-cancer (HR = 0.69, 95% CI = 0.60-0.79) mortality in the first 5 years of follow-up. These associations were attenuated over follow-up, but even after 10 years of follow-up, associations remained inverse (all-cause: HR = 0.89, 95% CI = 0.84-0.96; all-cancer: HR = 0.87, 95% CI = 0.78-0.97) after full adjustment. Individuals with IBS had decreased risk of mortality from breast, prostate, and colorectal cancers in some of the follow-up time categories. DISCUSSION: We found that earlier during follow-up, having diagnosed IBS was associated with lower mortality risk, and the association attenuated over time. Additional studies to understand whether specific factors, such as lifestyle and healthcare access, explain the inverse association between IBS and mortality are needed.
引用
- Li F, Yano Y, Étiévant L, et al. The Time-Dependent Association Between Irritable Bowel Syndrome and All-Cause and Cause-Specific Mortality: A Prospective Cohort Study Within the UK Biobank. Am J Gastroenterol. 2024. PMID: 38275237. doi:10.14309/ajg.0000000000002675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。